drugset / Trial / NCT05153317

Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis (CF) Participants 2 Years and Older

NCT05153317

Phase 3 Completed 71 enrolled Vertex Pharmaceuticals Incorporated
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the long term safety, tolerability, efficacy and pharmacodynamics of elexacaftor (ELX)/tezacaftor (TEZ)/ivacaftor (IVA) in CF participants 2 years of age and older.

Timeline

Start
2022-01-17
Primary completion
2026-01-29
Completion
2026-01-29

Drugs

EvaluationDrugModalityDoseRoute
Subject Ivacaftor Other / unclassified Oral
Subject elexacaftor Small molecule Oral
Subject tezacaftor Other / unclassified Oral

Indications